Related Experiment Video
Updated: Jan 5, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Non-invasive urinary biomarkers of renal function in sickle cell disease: an overview
Marília Rocha Laurentino1, Sérgio Luiz Arruda Parente Filho2, Lívia Leal Chagas Parente3
1Post-Graduation Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ceara, Capitão Francisco Pedro, Street, n.1210 - Rodolfo Teófilo, Fortaleza, Ceara, CEP 60430-370, Brazil. marilialaurentino@gmail.com.
Insights
Sickle cell disease (SCD) causes significant kidney damage, leading to end-stage renal disease (ESRD). New biomarkers like KIM-1, NGAL, and MCP-1 show promise for early detection of kidney injury in SCD patients.
Area of Science:
- Hematology
- Nephrology
- Genetics
Background:
- Sickle cell disease (SCD) is an inherited disorder caused by the hemoglobin S (HbS) gene.
- SCD leads to severe complications including chronic hemolysis, endothelial damage, and vaso-occlusion, resulting in multi-organ damage.
- Kidney impairment is a frequent complication of SCD, manifesting as urinary issues, glomerulopathies, proteinuria, hematuria, and often progressing to end-stage renal disease (ESRD).
Purpose of the Study:
- To investigate novel biomarkers for early diagnosis of kidney damage in sickle cell disease.
- To assess the potential of kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein 1 (MCP-1) as indicators of renal impairment in SCD.
Main Methods:
- The study focuses on evaluating the utility of specific novel biomarkers.
- Methods involve assessing KIM-1, NGAL, and MCP-1 levels in patients with SCD.
- These biomarkers are analyzed in relation to established indicators of renal function and damage.
Main Results:
- Preliminary findings suggest that KIM-1, NGAL, and MCP-1 may serve as early indicators of renal injury in SCD.
- These biomarkers could potentially detect kidney damage before significant functional decline or overt symptoms appear.
- Further research is needed to validate these findings and establish clinical utility.
Conclusions:
- Early detection of kidney damage in SCD is crucial for timely intervention and management.
- Novel biomarkers such as KIM-1, NGAL, and MCP-1 hold promise for improving the diagnosis of renal complications in SCD.
- Continued investigation into these biomarkers could lead to better patient outcomes and reduced progression to ESRD.
Abstract:
Sickle cell disease (SCD) is a hereditary condition characterized by homozygosis of the hemoglobin S (HbS) gene. Marked morbimortality is observed due to chronic hemolysis, endothelial injury, and episodes of vaso-occlusion, which leads to multi-organ damage. Renal impairment is common and may have different presentations, such as deficiency in urinary acidification or concentration, glomerulopathies, proteinuria, and hematuria, frequently resulting in end-stage renal disease (ESRD). Novel biomarkers of renal function, such as kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein 1 (MCP-1) are being studied in order to enable early diagnosis of kidney damage in SCD.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Serum Studies: Renal Function Tests
Urine Studies I: Urinalysis
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Acute Kidney Injury I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management

